This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Bristol Myers Squibb and Pfizer will begin offering ...
In a direct-to-patient move likely to reverberate across the pharmaceutical landscape, Bristol-Myers Squibb and Pfizer announced today they will begin offering their blockbuster blood thinner Eliquis ...
Eliquis Offered to Cash-Paying Patients at More Than 40% Discount to Current List Price, Sotyktu at More Than 80% Discount to Current List Price "We are proud to now offer Sotyktu at a lower price via ...
Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount. The move comes as the Trump ...
The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 ...
(RTTNews) - Bristol Myers Squibb (BMY) and Pfizer (PFE) Thursday announced a direct-to-patient option for purchasing their blood thinner medicine, Eliquis through the partnership's patient resource ...
Bristol-Myers Squibb Company has had a recent 30% stock decline amid concerns over patent expirations. Click here to read why BMY stock is a Hold.
Bloomberg on MSN
Bristol Raises Guidance on Demand for Eliquis, New Drugs
(Bloomberg) -- Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and ...
Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount. Stream San Diego News for free, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback